Depression is accompanied by metabolic disorders in
iron metabolism,
lipoproteins, and
insulin resistance. We measured plasma levels of
ferritin,
iron,
lipids,
insulin, and
glucose and computed the homeostasis model assessment (HOMA2IR) and atherogenic index of plasma (AIP) in MS patients with and without depression and healthy controls. Explanatory variables were serum
uric acid,
interleukin (IL)-6,
lipid hydroperoxides (CL-LOOH),
albumin, and
C-reactive protein (CRP). Depression was assessed using the Hospital Anxiety and Depression Scale (
HADS), neurological disability using the Expanded Disability Status Scale (EDSS), and
disease progression using ∆EDSS over five years earlier. HOMA2IR and
insulin were predicted by diagnosis (increased in MS), age and body mass index (BMI); AIP by diagnosis, sex, BMI, CRP, and
uric acid;
triglycerides by diagnosis (higher in MS without depression), age, BMI and
uric acid;
ferritin by diagnosis (higher in MS), sex, CRP, and
albumin; and
iron by
albumin. The
HADS score was significantly predicted by ∆EDSS, gastro-intestinal symptoms,
iron (inverse), and age. MS is characterized by significantly increased
insulin resistance, which is determined by increased
insulin levels; and increased
ferritin, a
biomarker of
inflammation. Depression in MS is not associated with increased
insulin resistance and atherogenicity but with lowered
iron.